Cleared Abbreviated

K133823 - NUFACE MINI DEVICE

K133823 is an FDA 510(k) clearance for NUFACE MINI DEVICE, manufactured by Carol Cole Company. The device is a Class 2 Neurology device with product code NFO cleared through the Abbreviated 510(k) pathway after a 121-day FDA review.

K133823 · Carol Cole Company · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2014
Decision
121d
Days
Class 2
Risk

K133823 is an FDA 510(k) clearance for the NUFACE MINI DEVICE. Classified as Stimulator, Transcutaneous Electrical, Aesthetic Purposes (product code NFO), Class II - Special Controls.

Submitted by Carol Cole Company (Vista, US). The FDA issued a Cleared decision on April 17, 2014 after a review of 121 days - within the typical 510(k) review window.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5890 - the FDA neurology device framework. The Abbreviated 510(k) pathway was used, relying on FDA-recognized standards to demonstrate substantial equivalence.

Device pattern: Standards-based predicate clearance. Standards-verified equivalence. The Abbreviated pathway signals strong alignment with FDA-recognized performance standards - typically associated with lower review burden and faster clearance cycles.

View all Carol Cole Company devices

FDA 510(k) Submission Details - K133823

510(k) Number K133823 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 17, 2013
Decision Date April 17, 2014
Days to Decision 121 days
Submission Type Abbreviated
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
27d faster than avg
Panel avg: 148d · This submission: 121d
Pathway characteristics
Standards-based clearance path.

NFO Device Classification - Class 2, Special Controls

Product Code NFO Stimulator, Transcutaneous Electrical, Aesthetic Purposes
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5890
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.